Vimta Labs Ltd
Vimta Labs Q2 FY26 earnings call: Revenue & Margins
Q2 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
Vimta Labs expects continued growth primarily in pharmaceutical research and testing services and food testing, which form the major revenue contributors. Vimta Labs has reported strong growth with Q2 FY '26 revenue crossing INR 100 crores, up 22.3% YoY.
From Vimta Labs Ltd's Q2 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Vimta Labs expects continued growth primarily in pharmaceutical research and testing services and food testing, which form the major revenue contributors.
- All verticals—pharma, food, electronics—are anticipated to grow at similar rates (7.5% to 9%), with pharma dominating revenue share (~65%) and food contributing ~20%.
- Biologics and large molecule formulation development services are emerging growth areas, with commercialization expected by Q1 FY 2027.
- Expansion in capacity across all verticals (pharma, food, electronics, preclinical, GMP testing) has been done to support growth without immediate capacity constraints.
- Increasing client demand for biologics development and outsourcing trends will further boost pharma segment growth.
- International markets offer opportunities for new business and market share gain, particularly in pharma.
2 more points management made on revenue & sales performance
Profitability & Margins
See what Vimta Labs Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Vimta Labs has planned a total capex of around INR100 crores for the current financial year, on track as per plan.
- Biologics segment capex is around INR25 crores for this year, with a similar amount planned for the next year ('27).
- Capex is spread across pharmaceuticals, food, and electrical & electronic testing verticals.
- Investments focus on expanding capacities, including new equipment and infrastructure.
- Some capex backed by visibility from client pipelines; others are inherent to newly created capacities.
- Clinical research requires minimal capex as studies in patient populations are off-site.
2 more points management made on capital expenditure plans
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Vimta Labs Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The company did not provide explicit current orderbook or pending order values during the call.
- They mentioned having strong order pipelines, especially in the pharmaceutical segment, mainly supporting generic product development.
- Preclinical business supports both discovery (35%) and generic, specialty chemicals, regulatory work (65%).
- The clinical trial business pipeline is growing, with intensified business development operations.
- The newly added CMO/CRADS vertical is part of the expansion backed by visibility of pipelines and client interest.
- Expansion into biologics and formulation development is driven by growing demand and client requests.
2 more points management made on order book & pipeline
Vimta Labs Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹109 Cr, net profit ₹21 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Vimta Labs Ltd's management said in earlier quarters
- Q3 FY25 earnings call analysis →
- Q1 FY27 earnings call analysis →
- Q4 FY26 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
- Q4 FY23 earnings call →
- Q3 FY23 earnings call →
Others in Healthcare Services this season
- 3B Blackbio DX Ltd (Q2 FY26)
Q2 FY 2025-26 sales: ₹3042.83 Lakh (including COVID sales ₹10.23 Lakh), up from ₹2457.55 Lakh in Q2 FY 2024-25. Key concall takeaways from 3B Blackbio DX Ltd's…
- Unihealth Hospitals Ltd (Q2 FY26)
Nashik financial closure achieved via equity and bank debt (INR 22 crores from Bank of India). Key concall takeaways from Unihealth Hospitals Ltd's Q2 FY26…
- Indegene (Q2 FY26)
Indegene is making strategic investments ahead of the curve to capitalize on market opportunities over the next 6 to 8 quarters, which will cause near-term…
- Dr Lal Pathlabs Ltd (Q2 FY26)
Sustained 11%-12% revenue growth without price hikes is planned, driven by increased patient volume and revenue per patient. Key concall takeaways from Dr Lal…
Frequently Asked Questions
What were Vimta Labs Ltd Q2 FY26 results?
Vimta Labs expects continued growth primarily in pharmaceutical research and testing services and food testing, which form the major revenue contributors. Vimta Labs has reported strong growth with Q2 FY '26 revenue crossing INR 100 crores, up 22.3% YoY.
What is Vimta Labs Ltd share price analysis?
Vimta Labs Ltd currently shows a neutral. The stock trades at a P/E of 34.1 with a market cap of ₹2,757 Cr. Investors should review the full earnings analysis for detailed insights.
Is Vimta Labs Ltd planning capital expenditure?
Vimta Labs has planned a total capex of around INR100 crores for the current financial year, on track as per plan.
Keep Vimta Labs Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.